Teva asks US Supreme Court to stay ruling in Copaxone case


Teva has filed an application with the US Supreme Court to stay a ruling by the US Court of Appeals for the Federal Circuit that allowed generic drug makers to enter the market before the expiry of Teva’s patents covering its $4.3 billion-a-year multiple sclerosis drug Copaxone (glatiramer acetate).

Teva, Copaxone, US Supreme Court, mandate stay, Federal Circuit